Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial

S Chandarlapaty, D Chen, W He, P Sung… - JAMA …, 2016 - jamanetwork.com
Importance Estrogen receptor α (ESR1) mutations found in metastatic breast cancer (MBC)
promote ligand-independent receptor activation and resistance to estrogen-deprivation …
被引用次数：488 相关文章

[引用][C] Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer

S Chandarlapaty, D Chen, W He, P Sung, A Samoila… - JAMA Oncology, 2016 - cir.nii.ac.jp
Prevalence of <i>ESR1</i> Mutations in Cell-Free DNA and Outcomes in Metastatic Breast
Cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial

S Chandarlapaty, D Chen, W He, P Sung… - JAMA …, 2016 - pubmed.ncbi.nlm.nih.gov
Importance Estrogen receptor α (ESR1) mutations found in metastatic breast cancer (MBC)
promote ligand-independent receptor activation and resistance to estrogen-deprivation …

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial

S Chandarlapaty, D Chen, W He, P Sung, A Samoila… - JAMA, 2016 - jamanetwork.com
OBJECTIVE To determine the prevalence of ESR1 mutations (Y537S and D538G) in
estrogen receptor (ER)-positive MBC and determine whether mutation is associated with …
[PDF] researchgate.net

[PDF][PDF] Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer A Secondary Analysis of the BOLERO-2 Clinical Trial

S Chandarlapaty, D Chen, W He, P Sung, A Samoila… - 2016 - researchgate.net
OBJECTIVE To determine the prevalence of ESR1 mutations (Y537S and D538G) in
estrogen receptor (ER)-positive MBC and determine whether mutation is associated with …

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

S Chandarlapaty, D Chen, W He, P Sung… - JAMA …, 2016 - europepmc.org
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A
Secondary Analysis of the BOLERO-2 Clinical Trial. - Abstract - Europe PMC Sign in | Create an …
[HTML] nih.gov

[HTML][HTML] Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial

S Chandarlapaty, D Chen, W He, P Sung… - JAMA …, 2016 - ncbi.nlm.nih.gov
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
[HTML] nih.gov

[HTML][HTML] Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial

S Chandarlapaty, D Chen, W He, P Sung… - JAMA …, 2016 - ncbi.nlm.nih.gov
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer -
PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

S Chandarlapaty, D Chen, W He, P Sung… - JAMA …, 2016 - europepmc.org
Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A
Secondary Analysis of the BOLERO-2 Clinical Trial. - Abstract - Europe PMC Sign in | Create an …